Akron Nephrology Associates

Akron, Ohio 44302

0 studies enrolling now · 2 studies all time

What they study most

Alport Syndrome, Focal Segmental Glomerulosclerosis

Studies at this site

• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis — Completed